RetaMaps

Active Medical Group

Active Medical Group · 4801 North Butler Avenue · Farmington, NM 87401

4.9· 91 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • GLP-1 medications named on site
  • Medically supervised weight loss
  • Endocrine / metabolic care

About this practice

Active Medical Group is a weight-loss and testosterone replacement clinic in Farmington, New Mexico, that also offers hormone therapy for women, according to its website. The site describes combining medical treatment with a holistic approach, including customized nutrition and lifestyle plans, FDA-approved medications and ongoing monitoring, and the practice lists semaglutide and tirzepatide. It holds a 4.9-star Google rating across 91 reviews dating back to 2023, with 13 in the past year; reviewers most often mention the providers' knowledge and the staff, and 17 reviews mention scheduling.

Services & access

Advertises semaglutide todayYes
Advertises tirzepatide todayYes
Telehealth visitsNot listed
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.9
Google rating · 91 reviews
13
reviews in the past year (avg ★ 5.0)
1
reviews mention GLP-1 medications
6
reviews mention weight loss

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-10. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.9 across 91 Google reviews. Of the 91 reviews we analyzed, 89 (98%) are positive (4–5★) and 2 (2%) are negative (1–2★).

What patients like

  • Knowledgeable, professional providers29 reviews
  • Friendly, helpful staff28 reviews
  • Feeling listened to22 reviews
  • Easy scheduling and communication16 reviews

Common complaints

  • Staff or front-desk issues2 of 2 negative
5★
89
4★
0
3★
0
2★
0
1★
2

Most recent Google reviews

Shawn L.★★★★★2026-09-10

Every time I have had a visit everyone is so nice and easy to talk to. Ashley takes the time to listen to what is going on with your health. Communication is great.

Mandy Q.★★★★★2026-08-26

I can’t thank Active Medical enough! You’ve truly given me back the energy I’ve been missing for years, and I’m so grateful!

Melissa F.★★★★★2026-08-24

Absolutely LOVE Ashley! She takes the time to listen to your needs and concerns and then FIXES them! Terri is also amazing, she is so friendly and fast! Gets you in and out and on your way! 10/10 recommend!

Gerald B.★★★★★2026-06-25

I had a fantastic consultation with Ashley today. She was super personable, knowledgeable, and genuinely great to talk to. I am very happy I found Active Medical Group, and am eager to see where my health can go!

Nathan D.★★★★★2026-06-02

Ashley has been great. She has helped my wife and I get through some trying times.

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Farmington

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs